Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target

International Journal of Cardiology

Volumn 243, Issue , 2017, Pages 86-90

  Di Franco, Alessandra ^a   Cantini, Giulia ^a   Tani, Alessia ^b   Coppini, Raffaele ^a   Zecchi Orlandini, Sandra ^b   Raimondi, Laura ^a   Luconi, Michaela ^a   Mannucci, Edoardo ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cardiac hypertrophy; Empagliflozin; Heart failure; Ischemic heart disease; Myocardial disease; SGLT1; SGLT2

Indexed keywords

EMPAGLIFLOZIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIAC MUSCLE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; HEART; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CARDIAC MUSCLE; CELL CULTURE; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM;

CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020133383     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.05.032     Document Type: Article

References (15)

1. Zinman, B., Lachin, J.M., Inzucchi, S.E., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 374(11), 2016, 1094.
2. Luconi, M., Raimondi, L., Di Franco, A., Mannucci, E., Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. Nutr. Metab. Cardiovasc. Dis. 26:12 (2016), 1071–1078.
3. Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14:1 (2012), 83–90.
4. von Lewinski, D., Rainer, P.P., Gasser, R., et al. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism, 59(7), 2010, 1020-8.
5. Vrhovac, I., Balen Eror, D., Klessen, D., et al. Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch., 467(9), 2015, 1881-98.
6. Lombardi, A., Cantini, G., Piscitelli, E., et al. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler. Thromb. Vasc. Biol., 28(4), 2008, 718-24.
7. +/glucose cotransporter 1 (SGLT1). J. Cell. Biochem., 90(2), 2003, 339-46.
8. Banerjee, S.K., McGaffin, K.R., Pastor-Soler, N.M., Ahmad, F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc. Res., 84(1), 2009, 111-8.
9. Castaneda-Sceppa, C., Subramanian, S., Castaneda, F., Protein kinase C mediated intracellular signaling pathways are involved in the regulation of sodium-dependent glucose co-transporter SGLT1 activity. J. Cell. Biochem., 109(6), 2010, 1109-17.
10. Arad, M., Benson, D.W., Perez-Atayde, A.R., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest., 109, 2002, 357e62.
11. Ramratnam, M., Sharma, R.K., D'Auria, S., et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J. Am. Heart Assoc., 3(4), 2014.
12. Coppini, R., Ferrantini, C., Yao, L., et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation, 127(5), 2013, 575-84.
13. Balteau, M., Tajeddine, N., de Meester, C., et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc. Res., 92(2), 2011, 237-46.
14. Hamouda, N.N., Qureshi, M.A., Alkaabi, J.M., Oz, M., Howarth, F.C., Reduction in the amplitude of shortening and Ca(2 +) transient by phlorizin and quercetin-3-O-glucoside in ventricular myocytes from streptozotocin-induced diabetic rats. Physiol. Res., 65(2), 2016, 239-50.
15. Baartscheer, A., Schumacher, C.A., Wüst, R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60:3 (2017), 568–573.